Table 2

The characteristics of the included studies (n=9)

Study
country
Study type
(total population)
ComorbiditiesValidationOSA prevalence (%)OSA definitionNo OSA AHI <5 (n)Mild OSA AHI ≥5 to <15 (n)Moderate-to-severe OSA AHI ≥15 to <30 or RDI ≥15 to <30 (n)Severe OSA AHI ≥30 or RDI ≥30 (n)
Petta et al)
Italy28
Prospective
(50)
Non-alcoholic fatty liver diseaseHSAT (Somnea, Compumedics)50.0AHI ≥525
(50.0%)
25
(50.0%)
Westlake et al
Czech Republic29
Prospective
(294)
DMHSAT (Apnoea Link)72.4AHI ≥581121
(41.2%)
61
(20.7%)
31
(10.5%)
Abumuamar et al
Canada30
Prospective
(95)
AFibHSAT
(Somté PSG)
85.3AHI ≥51435
(36.8%)
22
(23.2%)
24
(25.3%)
Kee et al
Australia31
Prospective
(758)
DM (512)
Obesity (129)
HTN (74)
HF (43)
HSAT
(Apnoea Link)
75.5REI ≥5186286
(37.7%)
184
(24.3%)
102
(13.5%)
Reuter et al
Germany32
Prospective
(85)
HTN (77)
AFib (23)
CHD (19)
HF (16)
CKD/ESRD (15)
DM (13)
Hyperlipidaemia (13)
Hyperuricaemia (12)
Valvular heart disease (12)
COPD/asthma (9)
ICD (8)
CVA (8)
HSAT
(Nox T3 Sleep Monitor)
37.7AHI ≥1553
(62.4%)
32
(37.6%)
Teng et al
China33
Prospective
(262)
DMLab PSG84.7AHI ≥54055
(21.0%)
83
(31.7%)
84
(32.1%)
Zeng et al
China34
Prospective
(102)
CVALab PSG56.9AHI ≥1544
(43.1%)
58
(56.9%)
Chen et al
China35
Retrospective
(221)
CVALab PSG74.7AHI ≥55649
(22.2%)
43
(19.5%)
73
(33.0%)
Felfeli et al
Canada36
Prospective
(27)
Retinal vein occlusionLab PSG96.3AHI ≥515
(18.5%)
10
(37.0%)
11
(40.7%)
  • AD, Alzheimer’s disease; AFib, atrial fibrillation; AHI, Apnoea–Hypopnoea Index; CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVA, cerebral vascular accident; DM, diabetes mellitus; ESRD, end-stage renal disease; HF, heart failure; HSAT, Home Sleep Apnoea Testing; HTN, hypertension; ICD, implantable cardioverter-defibrillator; OSA, obstructive sleep apnoea; Lab PSG, Laboratory PSG; PSG, polysomnography; RDI, Respiratory Disturbance Index; REI, Respiratory Event Index; RF, renal failure.